Market Access News | pharmaphorum

News

Syndax gets FDA okay for first-in-class leukaemia drug

A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.

News

PTC gets FDA okay for first brain-delivered gene therapy

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US.

News

Sanofi wins appeal in spat with NICE over Sarclisa

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM).

News

Scrabble letters spelling out 'Learn from failure'

Daiichi and AZ pull Dato-DXd filing with FDA and try again

Nine months after filing their TROP2-directed antibody-drug conjugate Dato-DXd for a lung cancer indication with the FDA, Daiichi Sankyo and AstraZeneca have pulled the submission.

News

NHS England relaunches anti-smoking pill programme

A daily pill that helps people stop smoking is to be offered by the NHS in England once again after it was withdrawn from sale in 2021 due to quality issues.

News

Unicycive eyes June FDA verdict for hyperphosphataemia drug

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease (CKD) who need dialysis, which hopes to improve on 'onerous' phos

Syndax gets FDA okay for first-in-class leukaemia drug

PTC gets FDA okay for first brain-delivered gene therapy

Sanofi wins appeal in spat with NICE over Sarclisa

Daiichi and AZ pull Dato-DXd filing with FDA and try again

NHS England relaunches anti-smoking pill programme

Unicycive eyes June FDA verdict for hyperphosphataemia drug

Sanofi gives up on amlitelimab in atopic dermatitis

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks